Member Info for kitchens

says full on bull,i can almost hear the doubters agreeing lmao

jump on now jump of at 6 jump back in at 5 etc etc and hope you dont miss the finaley

nicer design aswell,these have good neighbhours in my punt portfolio jv potential if they strike

patient it scares me

dont know how but i missed this http://www.fox-davies.com/media/49908/angusrossflashnote12thmay2009.pdf

were all big boys if its your money it should be your research and your responsable its always the same if something doesnt double overnight its treated like the end of the world,im sure this and RRR will be a lot higher in a years time i think people should be realistic, anyway best of luck whatever your in

to me first drug missed target but sound like they have new target for it share options for keegan at 10p happy days multibag here

havent a clue but one thing for sure is it will be going up little patience i think this is going to be goody

http://www.advfn.com/p.php?pid=nmona&cb=1243594953&article=37948770&symbol=L%5EMPM ALL GOOD 10P

http://www.advfn.com/p.php?pid=nmona&cb=1243594749&article=37948703&symbol=L%5EMPM

i suppose it was aimed at the people accusing you of ramping (we all press our own buttons GL )

Ha ha ive just posted on UVEL

oh thanks for doing the research taking the time to get the info interpretating it for and forcing me to press the button LMFAO and a guarentee if i dont make money im chuffed to bits

lets hope the warm weather reveal more goodies in greenland

lol still sitting on-30% ouch

its out the kumo

Whilst the outcome of the TEMPUS study of tonabersat in migraine prevention was disappointing, tonabersat's novel mode of action suggests that it has the potential to be clinically effective in treating a range of neurological conditions. There remains every possibility that tonabersat will become an approved product in the future, once the most appropriate indications are identified. still 2 drugs in the pipeline though Minster has rights to tonabersat in epilepsy, neuropathic pain and in other neurological indications where current treatments are inadequate, and we remain confident that the compound has significant therapeutic potential.

this hasnt made some ground today rns is good Highlights * Continued clinical progress during the year including positive Phase II results of tonabersat in the treatment of migraine with aura but disappointing results of Phase IIb results of tonabersat in the prevention of migraine * On-going mechanistic work on tonabersat's novel mode of action provides confidence that tonabersat has significant therapeutic potential in a range of indications * Clinical development pathway of sabcomeline moving closer to definition as an adjunct therapy to existing atypical neuroleptic drugs * Respected healthcare analyst Karl Keegan joined Minster as Chief Financial Officer in April 2009 * Cash and cash equivalents of GBP6.34 million at 31 March 2009 (2008: GBP11.8 million) and post-tax loss of GBP6.31 million (2008: GBP4.58 million) John Russell, Minster Pharmaceuticals' Chairman, said: "The Board intends to evaluate all opportunities to build shareholder value through our existing pipeline assets, our revitalised management team and our willingness to consider all options to deliver our ultimate goal of building a profitable business. We are currently refining our strategy in order to achieve this goal and look forward to updating shareholders in due course."

http://www.advfn.com/p.php?pid=nmona&cb=1243491849&article=37921389&symbol=L%5EMPM

+5%